291 related articles for article (PubMed ID: 26739236)
1. BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
Sahtoe DD; van Dijk WJ; Ekkebus R; Ovaa H; Sixma TK
Nat Commun; 2016 Jan; 7():10292. PubMed ID: 26739236
[TBL] [Abstract][Full Text] [Related]
2. The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.
Daou S; Hammond-Martel I; Mashtalir N; Barbour H; Gagnon J; Iannantuono NV; Nkwe NS; Motorina A; Pak H; Yu H; Wurtele H; Milot E; Mallette FA; Carbone M; Affar el B
J Biol Chem; 2015 Nov; 290(48):28643-63. PubMed ID: 26416890
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.
Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor HF; Sun ZW; Ezell RJ; Vaidya A; Meiners MJ; Cheek MA; Rice WJ; Svetlov V; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
Sci Adv; 2023 Aug; 9(32):eadg9832. PubMed ID: 37556531
[TBL] [Abstract][Full Text] [Related]
4. Familial and Somatic
Peng H; Prokop J; Karar J; Park K; Cao L; Harbour JW; Bowcock AM; Malkowicz SB; Cheung M; Testa JR; Rauscher FJ
Cancer Res; 2018 Mar; 78(5):1200-1213. PubMed ID: 29284740
[TBL] [Abstract][Full Text] [Related]
5. Retracted: Histone H2B ubquitination regulates retinoic acid signaling through the cooperation of ASXL1 and BAP1.
Lee SW; Youn H; Kim EJ; Um SJ
Mol Cell; 2013 Jul; 51(2):200-10. PubMed ID: 23850490
[TBL] [Abstract][Full Text] [Related]
6. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation.
Campagne A; Lee MK; Zielinski D; Michaud A; Le Corre S; Dingli F; Chen H; Shahidian LZ; Vassilev I; Servant N; Loew D; Pasmant E; Postel-Vinay S; Wassef M; Margueron R
Nat Commun; 2019 Jan; 10(1):348. PubMed ID: 30664650
[TBL] [Abstract][Full Text] [Related]
7. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis for the Activation of the Deubiquitinase Calypso by the Polycomb Protein ASX.
De I; Chittock EC; Grötsch H; Miller TCR; McCarthy AA; Müller CW
Structure; 2019 Mar; 27(3):528-536.e4. PubMed ID: 30639226
[TBL] [Abstract][Full Text] [Related]
9. Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase.
Ge W; Yu C; Li J; Yu Z; Li X; Zhang Y; Liu CP; Li Y; Tian C; Zhang X; Li G; Zhu B; Xu RM
Nature; 2023 Apr; 616(7955):176-182. PubMed ID: 36991118
[TBL] [Abstract][Full Text] [Related]
10. Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.
Peng H; Cassel J; McCracken DS; Prokop JW; Sementino E; Cheung M; Collop PR; Polo A; Joshi S; Mandell JP; Ayyanathan K; Hinds D; Malkowicz SB; Harbour JW; Bowcock AM; Salvino J; Kennedy EJ; Testa JR; Rauscher FJ
Mol Cancer Res; 2021 Jul; 19(7):1099-1112. PubMed ID: 33731362
[TBL] [Abstract][Full Text] [Related]
11. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.
Daou S; Barbour H; Ahmed O; Masclef L; Baril C; Sen Nkwe N; Tchelougou D; Uriarte M; Bonneil E; Ceccarelli D; Mashtalir N; Tanji M; Masson JY; Thibault P; Sicheri F; Yang H; Carbone M; Therrien M; Affar EB
Nat Commun; 2018 Oct; 9(1):4385. PubMed ID: 30349006
[TBL] [Abstract][Full Text] [Related]
12. Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Fukuda T; Tsuruga T; Kuroda T; Nishikawa H; Ohta T
Curr Cancer Drug Targets; 2016; 16(2):101-9. PubMed ID: 26517537
[TBL] [Abstract][Full Text] [Related]
13. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
[TBL] [Abstract][Full Text] [Related]
14. De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome.
Srivastava A; Ritesh KC; Tsan YC; Liao R; Su F; Cao X; Hannibal MC; Keegan CE; Chinnaiyan AM; Martin DM; Bielas SL
Hum Mol Genet; 2016 Feb; 25(3):597-608. PubMed ID: 26647312
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
Wu X; Bekker-Jensen IH; Christensen J; Rasmussen KD; Sidoli S; Qi Y; Kong Y; Wang X; Cui Y; Xiao Z; Xu G; Williams K; Rappsilber J; Sønderby CK; Winther O; Jensen ON; Helin K
Cell Res; 2015 Nov; 25(11):1205-18. PubMed ID: 26470845
[TBL] [Abstract][Full Text] [Related]
16. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1.
Zhang Y; Koppula P; Gan B
Cell Cycle; 2019 Apr; 18(8):773-783. PubMed ID: 30907299
[TBL] [Abstract][Full Text] [Related]
17. MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer.
Tsuboyama N; Szczepanski AP; Zhao Z; Wang L
Genome Biol; 2022 Sep; 23(1):206. PubMed ID: 36180891
[TBL] [Abstract][Full Text] [Related]
18. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB.
Scheuermann JC; de Ayala Alonso AG; Oktaba K; Ly-Hartig N; McGinty RK; Fraterman S; Wilm M; Muir TW; Müller J
Nature; 2010 May; 465(7295):243-7. PubMed ID: 20436459
[TBL] [Abstract][Full Text] [Related]
19. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
[TBL] [Abstract][Full Text] [Related]
20. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
